FVC · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in interstitial lung disease – FVC (% predicted) A lower percentage… compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Pulmonary arterial hypertension · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Overall mortality · people with systemic sclerosis
1 finding from 1 review
Event‐free survival · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional ability · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis
1 finding from 1 review
Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease. The study incorporated a ≥ 15% chance · people with systemic sclerosis
1 finding from 1 review
Event‐free survival · people with systemic sclerosis
Autologous non‐myeloablative selective HSCT probably leads to lower event‐free survival compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Pulmonary arterial hypertension · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with systemic sclerosis
1 finding from 1 review
Functional ability · people with systemic sclerosis
1 finding from 1 review
Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis
1 finding from 1 review
Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease · people with systemic sclerosis
1 finding from 1 review
Pulmonary arterial hypertension · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with systemic sclerosis
Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Overall mortality · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in overall mortality compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Event‐free survival · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in event‐free survival compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Relapse · SSNS in children
It is very uncertain whether levamisole changes relapse: at end of therapy compared with cyclophosphamide (very low certainty).
4 findings from 1 review
RR 2.14 [0.22, 20.95]
2 studies · 97 participants
Very low
RR 1.17 [0.76, 1.81]
2 studies · 97 participants
Low
RR 0.89 [0.68, 1.16]
1 study · 40 participants
Low
Show 1 more finding
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found